Project Grant R01DK148962
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $3.5M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of North Carolina at Chapel Hill a $222,758 Project Grant on August 7, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research through July 31, 2027. The award funds a comprehensive neuroscience investigation aimed at delineating how different molecularly defined dorsal root ganglia (DRG) neuron types contribute to pain representation...
- This $2,569,851 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), supports research to investigate how the PD-L1/PD-1 immune checkpoint pathway controls physiological and pathological pain, as well as opioid analgesia, through neuronal, immune, and glial mechanisms. The project aims to validate the actions of PD-L1 and the checkpoint inhibitor nivolumab on neuroinflammation and...
- This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.833 million on July 22, 2026, to investigate the role of TRP ion channels in migraine pain under the Drug Use and Addiction Research Programs (CFDA 93.279). The research examines how TRPV4 calcium ion channels in meningeal mast cells and satellite glial cells contribute to migraine pain and how this contribution varies by sex. The project employs trigeminal neuron–mast cell co-culture techniques, mast cell and...
- The National Institute of Neurological Disorders and Stroke awarded the University of Washington $176,500 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research deciphering the T cell receptor repertoire of painful human neuroma. The research aims to elucidate the role of T cells enriched within neuroma tissue from patients with chronic pain resulting from traumatic nerve injury. The recipient will profile the transcriptome and T cell receptor...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded The Johns Hopkins University a $2.71 million Project Grant (effective August 6, 2025 through July 31, 2030) under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neurobiological mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN). The award supports research utilizing novel whole dorsal root ganglia (DRG) in vivo imaging technology to monitor sensory...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded a $4.04 million Project Grant to the University of Texas at Dallas for a three-year initiative (September 1, 2025 through August 31, 2028) to identify and validate therapeutic targets for chronic pain treatment. The project leverages a CRISPR-based functional genomic screening platform developed by collaborating researchers at the University of Sydney and an extensive human dorsal root ganglion...
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
- The National Institute of Neurological Disorders and Stroke awarded Wake Forest University Health Sciences $426,250 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate sensory neuron-fibroblast crosstalk in knee osteoarthritis. The research examines how sensory neuron-derived calcitonin gene-related peptide (CGRP) regulates inflammation and fibrosis within joint tissue, contributing to osteoarthritis pain and disease progression. The work focuses...